Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in...
When Monica Bertagnolli, MD, was appointed director of the National Cancer Institute in 2022, she became the first woman...
The 2015 approval of an immune checkpoint inhibitor for renal cell carcinoma (RCC) provided a much-needed new treatment option...
The plenary program of the AACR Annual Meeting 2023 kicked off Saturday, April 15, with a session titled “Beating...
As 21,000 cancer researchers, clinicians, policymakers, and patient advocates thronged the Orange County Convention Center, Margaret Foti, PhD, MD...
The American Association for Cancer Research (AACR) is proud to offer Global Scholar-in-Training Awards (GSITA) to support the career...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...
The AACR Annual Meeting 2023 kicks off Friday, April 14, with thousands of cancer researchers from around the world...
As we welcome spring, enjoy the latest round of editors’ picks selected by the editors of AACR’s 10 journals....
Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We...